Gabapentin Tablet
Product Images NDC 71335-2038

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2038). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Equation (Gabapentin Equation)

The image shows a formula for calculating creatinine clearance (CLCr), involving age in years, weight in kilograms, and serum creatinine in mg/dL, with a multiplication adjustment factor for female patients. This formula is typically used to assess kidney function.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph depicting mean pain scores over 8 weeks under two treatment conditions: Placebo and Gabapentin 3600 mg/day. The X-axis shows weeks from baseline to week 8, and the Y-axis represents mean pain score. The graph is divided into a 4-week dose titration period and a 4-week fixed dose period, illustrating a decreasing pain score trend for Gabapentin compared to a relatively steady score for placebo.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph depicting mean pain scores over seven weeks, comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day treatment groups. The x-axis represents time in weeks including a 3-week dose titration period and a 4-week fixed dose period, while the y-axis shows mean pain scores ranging from 0 to 10. Gabapentin groups exhibit lower pain scores than placebo throughout.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart depicting the proportion of responders (patients with ≥ 50% reduction in pain score) at endpoint in two controlled postherpetic neuralgia (PHN) studies. Study 1 compares placebo (12%) with Gabapentin 3600 mg (29%). Study 2 compares placebo (14%) with Gabapentin 1800 mg (32%) and 2400 mg (34%). Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot showing the percentage difference on the y-axis against daily dose in mg on the x-axis for Gabapentin. Data points are marked for three different studies labeled a, b, and c, at doses 600 mg, 900 mg, 1200 mg, and 1800 mg. Each study uses a distinct symbol and the chart compares their results.*

FDA Label Image

Gabapentin-structure (Gabapentin Structure)

Chemical structure of Gabapentin, showing its molecular arrangement with a cyclohexane ring bonded to an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*

FDA Label Image

Label (Lbl713352038)

Gabapentin 800 mg (CV) tablet package label by Bryant Ranch Prepack. The label indicates the product compares to Neurontin 800 mg tablets by Alkem Laboratories Limited. It includes storage instructions to keep at 20°-25°C (68°-77°F) and a warning that the medication may cause dizziness. The package contains 90 tablets and the NDC is 71335-2038.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.